Surgery Doctors in Hastings, MI Accepting Medicare

3 Surgery doctors found. Showing 1 - 3

Dr. Max D Rappaport, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1005 W Green St, Suite 300, Hastings, MI 49058 Phone: 269-948-3632    Fax: 269-948-9874

David John Dargis, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 1005 W Green St Ste 300, Hastings, MI 49058 Phone: 269-948-8411

Dr. Brigit K Brennan, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1005 W Green St, Suite 300, Hastings, MI 49058 Phone: 269-948-3632    Fax: 269-948-9874

News Archive

Synexus on track to double its clinical trial capacity in South Africa, opens two new research centres in Pretoria

Manchester-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, celebrated the first phase of its South African expansion programme in Pretoria today.

Abortion continues to snag health reform legislation, divide lawmakers

The divisive issue of abortions, a lingering hurdle to health reform legislation, is plaguing both House and Senate Democratic leaders, the Los Angeles Times reports. "The delays in both houses reflect the fact that even though Democrats hold solid majorities, significant divisions exist below the surface.

Fortification of corn masa flour products could increase folic acid intake among Mexican-Americans

Fortification of corn masa flour products could increase folic acid intake by nearly 20 percent for Mexican-Americans, who are at a 30-40 percent higher risk for a number of severe brain and spinal birth defects, according to a study by the Centers for Disease Control and Prevention (CDC).

Investigational drug may hold benefit for patients with lung and ovarian cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.

Read more Medical News

› Verified 9 days ago